Tigecycline therapy for bacteremia and aortitis caused by Salmonella enterica serotype Choleraesuis: A case report

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 1, 2016, Pages 131-133

  Tang, Hung Jen ^a,b   Chen, Chi Chung ^c   Ko, Wen Chien ^d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Aortitis; Bacteremia; Salmonella enterica serotype Choleraesuis; Tigecycline

Indexed keywords

C REACTIVE PROTEIN; CEFAZOLIN; CIPROFLOXACIN; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ABDOMINAL PAIN; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AORTITIS; ARTICLE; BACKACHE; BACTEREMIA; BLOOD CULTURE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DYSPNEA; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LABORATORY TEST; LEUKOCYTOSIS; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOTIC ANEURYSM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; RASH; SALMONELLA ENTERICA SEROVAR CHOLERAESUIS; ANALOGS AND DERIVATIVES; ISOLATION AND PURIFICATION; MICROBIOLOGY; SALMONELLA ARIZONAE; SALMONELLA ENTERICA; SALMONELLA INFECTIONS; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; AORTITIS; BACTEREMIA; CIPROFLOXACIN; HUMANS; MALE; MINOCYCLINE; SALMONELLA ARIZONAE; SALMONELLA ENTERICA; SALMONELLA INFECTIONS; TREATMENT OUTCOME;

EID: 84958048238     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2012.01.011     Document Type: Article

References (16)

1. Vugia D.J., Samuel M., Farley M.M., Marcus R., Shiferaw B., Shallow S., et al. Invasive Salmonella infections in the United States, FoodNet, 1996-1999: incidence, serotype distribution, and outcome. Clin Infect Dis 2004, 38(Suppl. 3):S149-S156.
2. Chang H.R., Vladoianu I.R., Pechere J.C. Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella typhi within human monocyte-derived macrophages. J Antimicrob Chemother 1990, 26:689-694.
3. Lee H.Y., Su L.H., Tsai M.H., Kim S.W., Chang H.H., Jung S.I., et al. High rate of reduced susceptibility to ciprofloxacin and ceftriaxone among nontyphoid Salmonella clinical isolates in Asia. Antimicrob Agents Chemother 2009, 53:2696-2699.
4. Liu C.Y., Huang Y.T., Liao C.H., Hsueh P.R. In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan. Antimicrob Agents Chemother 2008, 52:2677-2679.
5. Sun H.K., Ong C.T., Umer A., Harper D., Troy S., Nightingale C.H., et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005, 49:1629-1632.
6. Ong C.T., Babalola C.P., Nightingale C.H., Nicolau D.P. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005, 56:498-501.
7. Tang H.J., Ko W.C., Chen C.C., Chen P.L., Toh H.S., Weng T.C., et al. Tigecycline against clinical non-typhoid Salmonella isolates: comparisons of in vitro and in vivo intracellular killing with Ceftriaxone. Antimicrob Agents Chemother 2011, 55:2755-2759.
8. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., Ellis-Grosse E.J. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006, 58:1221-1229.
9. MacGowan A.P. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008, 62(Suppl. 1):i11-i16.
10. Soravia-Dunand V.A., Loo V.G., Salit I.E. Aortitis due to Salmonella: report of 10 cases and comprehensive review of the literature. Clin Infect Dis 1999, 29:862-868.
11. Chen P.L., Wu C.J., Chang C.M., Lee H.C., Lee N.Y., Shih H.I., et al. Extraintestinal focal infections in adults with Salmonella enterica serotype Choleraesuis bacteremia. J Microbiol Immunol Inf 2007, 40:240-247.
12. Chang C.M., Lee H.C., Lee N.Y., Huang G.C., Lee I.W., Ko W.C. Cefotaxime-ciprofloxacin combination therapy for nontyphoid Salmonella bacteremia and paravertebral abscess after failure of monotherapy. Pharmacotherapy 2006, 26:1671-1674.
13. Neupane G.P., Kim D.M., Kim S.H., Lee B.K. In vitro synergism of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotypes Paratyphi A. Paratyphi B. Antimicrob Agents Chemother 2010, 54:3696-3701.
14. Paterson D.L., Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007, 45:1179-1181.
15. Gardiner D., Dukart G., Cooper A., Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010, 50:229-238.
16. Lefort A., Lafaurie M., Massias L., Petegnief Y., Saleh-Mghir A., Muller-Serieys C., et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003, 47:216-222.